EMA Endorses Track-and-Trace Recommendations
The agency is endorsing recommendations for global track-and-trace systems developed by the International Coalition of Medicines Regulatory Authorities.
The European Medicines Agency (EMA) announced on August 6, 2021 that it has endorsed the International Coalition of Medicines Regulatory Authorities (ICMRA) recommendations for global track-and-trace systems. ICMRA identifies, in a paper published by the organization, common technical denominators for systems to exchange and use drug and supply chain information. The interoperability of track-and-trace systems may help protect public health by sharing information on quality issues, drug shortages, and falsified medicines, according to the ICMRA paper, which was developed in consultation with the World Health Organization.
“Production and distribution of medicines are globalised and rapid exchange of information among regulatory authorities is integral to the protection of supply chain integrity and patient safety. Track and trace systems are considered to be a useful tool to mitigate the risk of shortages and fight production and marketing of falsified medicines. They provide visibility into the supply chain of medicines at any given time. However, until now, traceability systems have been designed and implemented with a local or regional focus, without taking into consideration whether they can exchange information with other systems at the global level,” EMA stated in a press release.
Source: EMA
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
